Abbott Prism HTLV-I/HTLV-II test 'reinforces blood supply safety position'
22 January 2008 00:00 in Medical Company Product News
Abbott has announced that the first fully-automated blood screening test for HTLV-1/HTLV-II designed for use with the Abbott Prism system has confirmed the company's position as the market leader in guaranteeing the safety of the world's blood supply.
The test will be used by laboratories wanting to screen donations of blood and plasma from individuals for antibodies for the human T ? lymphotropic virus Type I and/or human T ? lymphotropic virus Type II.
Both are distinct but closely related retroviruses associated with neurological disorders, human T-cell leukaemia and other diseases.
Robert Doss, divisional vice-president of diagnostics research and development at Abbott, said: "With the Abbott prism system, we continue to support the infectious disease testing needs of the laboratory while helping them realise greater efficiencies and enhanced operator safety throughout the blood and plasma screening process."
The HTLV-1/HTLV-II test recently received approval for use from the US Food and Drug Administration, while the Prism is currently includes four hepatitis tests and is used in over 30 countries worldwide.
Last week, Abbott reported that its newly-developed molecular test that can identify a variant strain of chlamydia received CE Mark certification in the European Union.
Other news stories from 22/01/2008
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency